Clarice Groeneveld, Jacqueline Fontugne, Luc Cabel, Isabelle Bernard-Pierrot, François Radvanyi, et al.. Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy.
European Journal of Cancer, Elsevier, 2021, 148, pp.181-189.
⟨10.1016/j.ejca.2021.01.036⟩.
⟨hal-03453779⟩